Novo Nordisk Secures EU CHMP Backing for Ozempic® Label Expansion in PAD, Reinforcing Semaglutide’s Role in Managing Type 2 Diabetes with Comorbidities Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP)…
Exelixis Reports Positive Phase 3 Results for Zanzalintinib and Atezolizumab Combo in Metastatic Colorectal Cancer Exelixis, has announced promising topline results from the STELLAR-303 phase 3 pivotal clinical trial, a major milestone in the development of its investigational therapy zanzalintinib.…
Sarclisa Moves Closer to EU Approval for Frontline Treatment of Transplant-Eligible Multiple Myeloma Patients The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of Sarclisa (isatuximab) in combination with…
Roche Unveils Promising Phase I/II Data for Next-Generation Bispecific Antibody NXT007 in Hemophilia A, Signaling a Major Step Toward Phase III Development Roche has shared encouraging new data from its early-stage clinical development program evaluating NXT007, a next-generation investigational bispecific…
Novo Nordisk’s CagriSema Delivers Up to 22.7% Weight Loss in Obese or Overweight Adults, REDEFINE 1 Trial Results Published in NEJM In a significant advancement for the treatment of obesity and overweight, Novo Nordisk today announced the publication of pivotal…
Novo Nordisk Unveils Positive Phase 3b Results for Mim8 in Hemophilia A: Seamless Switch from Emicizumab Shows Safety, Efficacy, and High Patient Satisfaction Novo Nordisk presented new findings from its pivotal phase 3b FRONTIER5 clinical trial at the 2025 International…
CHMP Recommends Expanded Use of Bayer’s Nubeqa™ (Darolutamide) for Advanced Prostate Cancer Following Positive ARANOTE Trial Results The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending Bayer’s oral…
Vertex Showcases Groundbreaking Data for Zimislecel in Type 1 Diabetes at ADA 85th Scientific Sessions Vertex Pharmaceuticals Incorporated has announced compelling new clinical data from its ongoing FORWARD-101 trial, underscoring the transformative potential of its investigational islet cell therapy, zimislecel…
FDA Approves Dupixent as the First and Only Targeted Therapy for Adults with Bullous Pemphigoid In a groundbreaking development for patients suffering from a rare and debilitating autoimmune skin disease, the U.S. Food and Drug Administration (FDA) has approved Dupixent…
Roche’s Lunsumio and Polivy Combination Marks Major Advance in Relapsed or Refractory Large B-Cell Lymphoma with Significant Remission Durability Roche has announced promising results from its pivotal Phase III SUNMO study (NCT05171647), demonstrating that its novel subcutaneous combination therapy of…
Civil Society Deepens Its Role in Shaping Global Health Policy at WHA78 At the 78th World Health Assembly (WHA78), held under the unifying theme “One World for Health,” a pivotal shift in the dynamics of global health governance was unmistakably…
Grifols’ BT524 Fibrinogen Therapy Shows Promise in Phase 3 Trial Published in The Lancet’s eClinicalMedicine Grifols, a globally recognized healthcare company and a leader in the production of plasma-derived therapies, has marked a significant advancement in the treatment of acquired…
